Chromax®: Chromium Picolinate for Carbohydrate Metabolism and Glucose Support

biostrips-chromax-insulin-receptor-signaling-diagram.webp

Chromax® is a registered form of chromium picolinate manufactured by Nutrition 21, LLC. Chromium is recognized by the US Institute of Medicine as an essential trace mineral with an established role in normal carbohydrate, protein, and fat metabolism. BIOSTRIPS® Glucose Support delivers 25 mcg of elemental chromium per serving as Chromax®, providing 71 percent of the daily value and meeting the lower bound of the IOM Adequate Intake range for adults.

What Is Chromax®?

Chromax® is a registered trademark of Nutrition 21, LLC, based in Harrison, New York. It is a patented form of chromium picolinate: chromium(III) bound to three molecules of picolinic acid. The chemical name is chromium(III) tris(picolinate). Chromax® contains 12.43 percent trivalent chromium by weight, yielding 25 mcg of elemental chromium per serving in the BIOSTRIPS® formulation.

Chromium is an essential trace mineral. The US Institute of Medicine established an Adequate Intake (AI) of 25 to 35 mcg per day of elemental chromium for adults, recognizing its role in normal carbohydrate, protein, and fat metabolism. No Tolerable Upper Intake Level has been set for trivalent chromium at nutritional doses, reflecting the strong safety record at levels consistent with dietary intake.

Chromax® qualifies as a dietary ingredient under US DSHEA (21 U.S.C. Section 321(ff)). The ingredient is commercially established and has been included in glucose support formulations globally for over two decades.

Manufacturer: Nutrition 21, LLC

How Does Chromax® Work?

Chromium is an essential trace mineral that contributes to normal carbohydrate metabolism as part of healthy metabolic function. Research has studied its role in insulin signaling, including effects on insulin receptor activity and related cellular processes. These studies help explain chromium’s contribution to maintaining normal carbohydrate metabolism in healthy adults (Anderson, 1997, Journal of the American College of Nutrition, PMID 9322187).

The proposed molecular mediator is chromodulin, a low-molecular-weight chromium-binding oligopeptide found in insulin-sensitive tissues. When chromium is absorbed and transported to cells, it binds to apochromodulin to form chromodulin, which then potentiates insulin receptor kinase activity. This mechanism amplifies the insulin signal without increasing insulin secretion.

At the BIOSTRIPS® serving dose of 25 mcg per day, chromium is providing nutritional support at the IOM Adequate Intake level, not a pharmacological intervention. The mechanism above describes the role of chromium as an essential nutrient in normal physiological function. Higher-dose chromium research sits in a separate, pharmacological range and is not the basis for the BIOSTRIPS® claim. The BIOSTRIPS® serving of 25 mcg is a nutritional support dose within the IOM Adequate Intake range for normal carbohydrate metabolism.

Picolinic acid, the ligand in chromium picolinate, enhances chromium absorption from the gastrointestinal tract compared to inorganic chromium salts such as chromium chloride, supporting more efficient delivery of the mineral at low nutritional doses.

Clinical Evidence and Regulatory Recognition

The substantiation approach for chromium in BIOSTRIPS® differs from Reducose® and is explicitly disclosed here. Chromax® at 25 mcg per serving is formulated at a nutritional support dose, not a clinical trial dose. The three primary Chromax® RCTs used doses of 200 to 1,000 mcg per day in populations with type 2 diabetes. Those trials are referenced below as mechanism evidence only. Primary substantiation for the BIOSTRIPS® chromium claim rests on chromium’s recognized nutritional role at the IOM Adequate Intake level.

IOM Dietary Reference Intakes for Chromium (2001)

Institute of Medicine Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press, Washington DC, 2001.

The IOM established an Adequate Intake of 25 mcg per day for adult women and 35 mcg per day for adult men, based on chromium’s recognized role in normal macronutrient metabolism. No Recommended Dietary Allowance was established due to insufficient data to define an average requirement, but the AI reflects the amount associated with apparent sufficiency in apparently healthy people. BIOSTRIPS® delivers 25 mcg per serving, meeting the female AI and providing 71 percent of the daily value as recognized by the FDA.

Anderson, 1997 — Journal of the American College of Nutrition — PMID 9322187

Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. Journal of the American College of Nutrition. 1997;16(5):404-410. PMID 9322187.

A comprehensive review of chromium’s role in glucose and insulin regulation. Anderson reviewed chromium’s role as a cofactor in insulin signaling, including its influence on insulin binding and receptor activity. The review noted that measurable effects were tied to chromium status: no additional effect was observed in people already at adequate chromium intake. This is consistent with chromium acting as an essential nutrient that supports normal metabolic function, not as a pharmacological agent.

Chromax® Clinical Trials: Mechanism Reference Only

The following three trials used Chromax® chromium picolinate at 1,000 mcg per day in populations with type 2 diabetes. They are cited here as supporting mechanism evidence for chromium’s role in glucose and insulin metabolism. They are not invoked as direct substantiation for the BIOSTRIPS® dose of 25 mcg per day, which is below the dose range studied in each trial.

Martin J et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. 2006;29(8):1826-1832. PMID 16873787. Dose: 1,000 mcg/day Chromax®.
Anton SD et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technology and Therapeutics. 2008;10(5):405-412. PMID 18715218. Dose: 1,000 mcg/day Chromax®.
Cefalu WT et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism. 2010;59(5):755-762. PMID 20022616. Dose: 1,000 mcg/day Chromax®.

Dosage and Standardization

The BIOSTRIPS® serving delivers 25 mcg of elemental chromium as Chromax® chromium picolinate, equal to 71 percent of the FDA daily value and the lower bound of the IOM Adequate Intake range of 25 to 35 mcg per day for adults.

Chromax® is a patented, highly characterized form of chromium picolinate with a documented chromium content of 12.43 percent trivalent chromium by weight. This precise specification ensures consistent elemental chromium delivery per serving, unlike commodity chromium chloride powders with variable mineral content.

The dose context is important. Published Chromax® RCTs used 200 to 1,000 mcg per day in clinical populations. The BIOSTRIPS® dose of 25 mcg is a nutritional support dose: it provides daily chromium within the IOM-recognized adequate range for normal metabolic function, not a pharmacological intervention.

Reference	Chromium Picolinate Dose	Population and Context	BIOSTRIPS® Dose
Martin et al., 2006. Diabetes Care. PMID 16873787	1,000 mcg/day (as Chromax®)	T2D adults. Mechanism reference: improved insulin sensitivity and attenuated weight gain.	25 mcg/day. Nutritional support level (71% DV)
Anton et al., 2008. Diabetes Technol Ther. PMID 18715218	1,000 mcg/day (as Chromax®)	T2D/obese adults. Mechanism reference: food intake and satiety effects.	25 mcg/day. Nutritional support level (71% DV)
Cefalu et al., 2010. Metabolism. PMID 20022616	1,000 mcg/day (as Chromax®)	T2D adults. Mechanism reference: metabolic and physiologic response characterization.	25 mcg/day. Nutritional support level (71% DV)
IOM Adequate Intake (2001)	25-35 mcg/day elemental chromium	Healthy adults. Established adequate daily intake for normal macronutrient metabolism.	25 mcg/day. Exact lower bound of AI range

Table 1. Dose comparison: clinical trials versus BIOSTRIPS® nutritional serving.

The takeaway: BIOSTRIPS® uses chromium at the nutritional level the IOM recognizes for normal metabolism, not at the elevated doses used in clinical research. The higher-dose studies are shown for context only.

Why Chromax® Is in BIOSTRIPS® Glucose Support

Chromax® was selected over commodity chromium chloride for two reasons: documented purity and a published safety record at doses substantially higher than the BIOSTRIPS® serving.

On purity, Chromax® is manufactured to a defined chromium content of 12.43 percent trivalent chromium by weight, with batch-to-batch consistency verified by Nutrition 21. Generic chromium picolinate powders sourced from commodity suppliers vary in purity and may contain trace contaminants from the synthesis process.

On safety record, Chromax® has been used in human clinical trials at doses up to 1,000 mcg per day, which is 40 times the BIOSTRIPS® serving. No serious adverse events have been reported in those trials. This published safety record at supratherapeutic doses relative to the BIOSTRIPS® serving provides a documented margin of safety.

Within the BIOSTRIPS® Glucose Support formulation, chromium contributes to the structure/function claim for healthy carbohydrate metabolism through its recognized role as an essential trace mineral, complementing Reducose® as the primary active ingredient.

“We chose Chromax® because it comes with a defined purity spec and a published human safety record. With chromium, the form and the source matter, and we weren’t willing to use a commodity powder.”

— Joanna Bacchus, Certified Nutritional Advisor and Founder, BIOSTRIPS®

Delivery mechanism: How BIOSTRIPS® Works | Full clinical evidence: Clinical Evidence

Is Chromax® Safe?

Trivalent chromium, the form in Chromax®, is recognized by the IOM as safe at nutritional intake levels. No Tolerable Upper Intake Level has been established for trivalent chromium, reflecting the absence of adverse effects at doses studied in humans. Chromax® has been used in human trials at up to 1,000 mcg per day with no serious adverse events reported.

Parameter	Detail	Assessment
BIOSTRIPS® dose	25 mcg elemental Cr/day (71% DV)	Within the IOM Adequate Intake range of 25-35 mcg/day for adults. No Tolerable Upper Intake Level (UL) has been established for trivalent chromium.
Chromax® clinical trial doses	200-1,000 mcg/day	Chromax® has been used in published human trials at doses up to 40x the BIOSTRIPS® serving with no serious adverse events reported. Nutrition 21 maintains a comprehensive safety dossier.
Trivalent vs hexavalent chromium	Trivalent Cr(III) form	Chromax® contains trivalent chromium(III) picolinate. Trivalent chromium is the biologically active, dietary form. Hexavalent chromium Cr(VI) is an industrial pollutant and toxicologically distinct. They are not interchangeable.
Genotoxicity	In vitro concern at high doses	One in vitro study raised a mutagenicity signal at supraphysiological concentrations (Stearns et al., 2002, Mutat Res, PMID 11719098). Subsequent regulatory review by the IOM and FDA found no basis to revise the Adequate Intake or restrict chromium picolinate as a dietary ingredient at nutritional doses.

Table 2. Safety context for Chromax® chromium picolinate at the BIOSTRIPS® serving dose.

Recommended Use

Adults 18 years and older.
Two strips taken 2 to 3 minutes before the first meal of the day. May also be taken before dinner. Maximum four strips per day.
Not recommended for pregnant or lactating women. Not specifically studied in these populations.

Consult a Healthcare Provider Before Use If You Are:

Diagnosed with diabetes, pre-diabetes, or any condition affecting blood glucose.
Taking insulin, sulfonylureas, metformin, or any other glucose-lowering medication.
Taking any prescription medication that affects blood sugar or carbohydrate metabolism.

Regulatory Status

Chromax® chromium picolinate qualifies as a dietary ingredient under DSHEA (21 U.S.C. Section 321(ff)). Chromium is also recognized as an essential nutrient by the FDA, which has established a daily value of 35 mcg for chromium on the Nutrition Facts panel. All structure/function claims for BIOSTRIPS® Glucose Support are framed under 21 CFR Section 101.93.

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions

What is Chromax®?

Chromax® is a patented form of chromium picolinate manufactured by Nutrition 21, LLC. It contains 12.43 percent trivalent chromium by weight and is standardized for consistent elemental chromium delivery. Chromax® qualifies as a dietary ingredient under US DSHEA.

How does Chromax® work?

Chromium in Chromax® is an essential trace mineral that supports normal carbohydrate metabolism. It participates in insulin signaling as part of normal carbohydrate metabolism. Chromium interacts with molecules like chromodulin to support healthy metabolic function. BIOSTRIPS® delivers 25 mcg per serving, providing nutritional support within the IOM Adequate Intake range.

What dose of chromium is in BIOSTRIPS®?

Each serving of BIOSTRIPS® Glucose Support (two strips) delivers 25 mcg of elemental chromium as Chromax®, equal to 71 percent of the FDA daily value. This meets the lower bound of the IOM Adequate Intake range of 25 to 35 mcg per day for adults.

Is the Chromax® dose in BIOSTRIPS® a clinical dose?

No. The 25 mcg per serving in BIOSTRIPS® is a nutritional support dose within the IOM Adequate Intake range. Published Chromax® clinical trials used doses of 200 to 1,000 mcg per day. The BIOSTRIPS® chromium claim is substantiated by chromium’s recognized nutritional role at the AI level, not by those clinical trials.

Is Chromax® the same as chromium chloride?

No. Chromax® is chromium(III) bound to picolinic acid, which enhances absorption from the gastrointestinal tract compared to inorganic chromium salts such as chromium chloride. Chromax® also carries a documented purity specification and published human safety data that commodity chromium powders do not.

Is chromium picolinate safe?

Trivalent chromium, including chromium picolinate, has no established Tolerable Upper Intake Level, reflecting the absence of adverse effects at doses studied in humans. Chromax® has been used in human trials at up to 1,000 mcg per day with no serious adverse events. The BIOSTRIPS® dose of 25 mcg is well within the IOM Adequate Intake range.

Chromax® versus chromium chloride: which is better?

Chromium picolinate, including Chromax®, is better absorbed than chromium chloride in most human studies. The picolinate ligand facilitates passive diffusion through the intestinal wall. Chromax® also carries a published clinical safety record at supratherapeutic doses. Chromium chloride is cheaper but lacks equivalent absorption data and published safety documentation.

Is chromium the same as chromium-6 (hexavalent chromium)?

No. Chromax® contains trivalent chromium, Cr(III), the biologically active dietary form found in food and recognized as an essential nutrient. Chromium-6, or hexavalent chromium Cr(VI), is an industrial pollutant and known carcinogen. They are chemically distinct and toxicologically unrelated. Confusion between the two is common but scientifically unwarranted.

Is BIOSTRIPS® vegan, gluten-free, and sugar-free?

Yes. BIOSTRIPS® Glucose Support Strips are vegan, sugar-free, and gluten-free, sweetened with steviol glycosides. The product carries Halal certification and is manufactured under GMP, HACCP, ISO 22000:2018, and FSSAI standards.

References

Citations verified against PubMed where applicable. Claim language conforms to DSHEA 21 CFR Section 101.93 and FTC substantiation standards.

Institute of Medicine Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academies Press, Washington DC, 2001. ncbi.nlm.nih.gov/books/NBK222317
Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. Journal of the American College of Nutrition. 1997;16(5):404-410. PMID 9322187. DOI: 10.1080/07315724.1997.10718703.
Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. 2006;29(8):1826-1832. PMID 16873787. Mechanism reference. Dose 1,000 mcg/day. T2D population.
Anton SD, Morrison CD, Cefalu WT, et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technology and Therapeutics. 2008;10(5):405-412. PMID 18715218. Mechanism reference. Dose 1,000 mcg/day.
Cefalu WT, Rood J, Pinsonat P, et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism. 2010;59(5):755-762. PMID 20022616. Mechanism reference. Dose 1,000 mcg/day. T2D population.
Broadhurst CL, Domenico P. Clinical studies on chromium picolinate supplementation in diabetes mellitus: a review. Diabetes Technology and Therapeutics. 2006;8(6):677-687. PMID 17109600. Clinical review.
Stearns DM et al. Chromium(III) tris(picolinate) is mutagenic at the hypoxanthine (guanine) phosphoribosyltransferase locus in Chinese hamster ovary cells. Mutation Research. 2002;513(1-2):135-142. PMID 11719098. In vitro safety reference.
Chromium picolinate. Wikipedia. en.wikipedia.org/wiki/Chromium_picolinate
Nutrition 21, LLC. Chromax® chromium picolinate. nutrition21.com
US FDA. 21 CFR Section 101.93: Structure/Function Claims. ecfr.gov